Parabilis Medicines, Inc.

Healthcare

NASDAQ:PBLS · NASDAQ Global Market

Market Cap $84.66M Beta 0.00
$25.85 +0.94%

+$0.25 today

52W Low $24.51High $34.47

Vol 0.67M · Avg 2.56M

Biotechnology

Management

Put operating results in leadership context

Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.

Return Metrics

ROE, ROIC & ROA over time

Management

No return metrics data available.

Management

Key executives, compensation & ownership

Management
NameTitleCompensationTenureAgeShares OwnedOwnership %

Mathai Mammen

CEO, President, Treasurer & Chairman$1.30M59

Teresa L. Jurgensen

Executive VP, Secretary & General Counsel$691,586.0048

Fawzi Benzaghou

Chief Medical Officer$408,169.0050

Jonathan Hurov

Executive Vice President of Discovery Biology

Rohin Mhatre

Chief Technical Operations Officer61

Jianing Di

VP of International R&D and Corporate Development

John McGee

Scientific Co-Founder, Executive Vice President & Head of Platform

Thomas Kotarakos

Chief Financial Officer44

Marie Nguyen

Senior VP & Head of Clinical Development

Kristen Stants

Chief People Officer53

Insider Trading

SEC Form 4 transactions — last 12 months

Management

No insider transactions in the last 12 months.

Growth Analysis

Historical CAGR & forward analyst estimates

No growth data available

Competitors

Peer companies in the same sector

Health

No competitor data available.

Who manages PBLS?

Parabilis Medicines, Inc. (PBLS) lists 10 active executives. The top listed executive is Fawzi Benzaghou, Chief Medical Officer.

Explore More

Continue the stock analysis

Jump to another research area for this company.